Comparative Pharmacology
Head-to-head clinical analysis: TIAMATE versus ZULRESSO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TIAMATE versus ZULRESSO.
TIAMATE vs ZULRESSO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tiamate is a combination of tiamulin (a pleuromutilin antibiotic) and valnemulin (a pleuromutilin antibiotic). Tiamulin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, specifically at the peptidyl transferase center, preventing peptide bond formation. Valnemulin similarly binds to the 50S subunit and inhibits protein synthesis.
Allopregnanolone is a positive allosteric modulator of GABAA receptors, enhancing phasic and tonic inhibition via binding to delta-subunit-containing receptors.
250 mg orally twice daily
Initial: 30 mcg/min IV infusion for 0-4 hours, then increase by 30 mcg/min every 4 hours if tolerated, maximum 120 mcg/min; typical duration up to 60 hours.
None Documented
None Documented
Terminal half-life 2–4 hours; dose adjustment needed in renal impairment (CrCl <30 mL/min)
Terminal elimination half-life is approximately 18 hours (range 15-23 hours) following intravenous administration; clinically, this supports once-daily dosing.
Primarily renal (70–80% as unchanged drug); biliary/fecal (20–30%)
Primarily via renal excretion as unchanged drug (approximately 90% of dose) and minor fecal elimination (approximately 5%); no active metabolites identified.
Category C
Category C
Antidepressant
Antidepressant